GSH-activatable rare-earth nanoprobe for NIR-II fluorescence imaging-guided surgery and enhanced chemotherapy/chemodynamic therapy of breast cancer
Cancer Letters · 2026-09 · 656 · 218677
DOI: 10.1016/j.canlet.2026.218677 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-09. Verfasst von Lin-Ling Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Breast Center and the Cancer Institute of Yunnan Cancer Hospital, Yunnan Key Laboratory of Molecular Imaging in Oncology, The Third Affiliated Ho…. Hauptthemen laut MEDLINE: Breast Neoplasms, Doxorubicin, Glutathione, Nanoparticles. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Yunnan Key Research and Development Program, Kunming Medical University, Xiamen Municipal Bureau of Science and Technology.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The precise intraoperative delineation of tumor margins and the controlled intratumoral release of chemotherapeutic agents remain major challenges in breast cancer therapy. Tumor microenvironment (TME)-responsive nanoplatforms provide a promising approach by utilizing the distinctive biochemical properties of tumors to achieve targeted imaging and treatment. Herein, we developed a glutathione (GSH)-activatable theranostic nanoprobe (DSM-cRGD) emitting fluorescence in the second near-infrared window (NIR-II). The probe is constructed from Nd-doped rare-earth nanoparticles coated with a manganese dioxide (MnO2) shell and functionalized with cyclic RGD peptide. The MnO2 shell quenches NIR-II fluorescence during systemic circulation and undergoes GSH-responsive degradation within the TME. In addition, the nanoprobe shows favorable tumor-targeting ability via specific binding to integrin αvβ3, thereby enabling real-time, high-contrast surgical navigation. Moreover, the newly developed therapeutic agent, DSM-cRGD@DOX, formed by loading doxorubicin (DOX) onto DSM-cRGD, enables the simultaneous release of DOX and Mn2+ ions upon degradation of the MnO2 shell in the TME, thereby inducing synergistic chemodynamic and chemotherapeutic effects. This further induces immunogenic cell death, which activates anti-tumor immune responses and suppresses tumor recurrence and metastasis. Collectively, this DSM-cRGD-based platform represents an integrated nanoplatform that combines precise tumor imaging with stimuli-responsive drug delivery, offering an advanced strategy for the precision management of breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Breast Center and the Cancer Institute of Yunnan Cancer Hospital, Yunnan Key Laboratory of Molecular Imaging in Oncology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking U…
- State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, 350002, China; Xiamen Key Laboratory of Rare Earth Photoelectric Functional Mat…
Förderung
- Yunnan Key Research and Development Program
- Kunming Medical University
- Xiamen Municipal Bureau of Science and Technology
- National Natural Science Foundation of China
Zitieren
APA
Lin, L. L., Bai, J. W., Song, L., Lou, K. L., Gao, Y. Y., Chen, H. Y., Lin, S. J., Li, C. X., Zhang, Y., & Zhang, G. J. (2026). GSH-activatable rare-earth nanoprobe for NIR-II fluorescence imaging-guided surgery and enhanced chemotherapy/chemodynamic therapy of breast cancer. Cancer Letters, 656, 218677. https://doi.org/10.1016/j.canlet.2026.218677
Vancouver
Lin LL, Bai JW, Song L, Lou KL, Gao YY, Chen HY, et al. GSH-activatable rare-earth nanoprobe for NIR-II fluorescence imaging-guided surgery and enhanced chemotherapy/chemodynamic therapy of breast cancer. Cancer Letters. 2026;656:218677. doi:10.1016/j.canlet.2026.218677
BibTeX
@article{Lin2026,
author = {Lin, Lin-Ling and Bai, Jing-Wen and Song, Liang and Lou, Kang-Liang and Gao, Yi-Yang and Chen, Hong-Yu and Lin, Sheng-Jie and Li, Cheng-Xi and Zhang, Yun and Zhang, Guo-Jun},
title = {GSH-activatable rare-earth nanoprobe for NIR-II fluorescence imaging-guided surgery and enhanced chemotherapy/chemodynamic therapy of breast cancer},
journal = {Cancer Letters},
year = {2026},
volume = {656},
pages = {218677},
doi = {10.1016/j.canlet.2026.218677}
}
EUVIMED